These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21671975)

  • 1. Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype.
    Moncada-Vélez M; Vélez-Ortega A; Orrego J; Santisteban I; Jagadeesh J; Olivares M; Olaya N; Hershfield M; Candotti F; Franco J
    Scand J Immunol; 2011 Nov; 74(5):471-81. PubMed ID: 21671975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
    Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.
    Liu P; Santisteban I; Burroughs LM; Ochs HD; Torgerson TR; Hershfield MS; Rawlings DJ; Scharenberg AM
    Clin Immunol; 2009 Feb; 130(2):162-74. PubMed ID: 18952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency.
    Hirschhorn R; Yang DR; Puck JM; Huie ML; Jiang CK; Kurlandsky LE
    Nat Genet; 1996 Jul; 13(3):290-5. PubMed ID: 8673127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
    Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
    J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
    Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
    J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery.
    Hirschhorn R; Yang DR; Israni A; Huie ML; Ownby DR
    Am J Hum Genet; 1994 Jul; 55(1):59-68. PubMed ID: 8023852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency.
    Serana F; Sottini A; Chiarini M; Zanotti C; Ghidini C; Lanfranchi A; Notarangelo LD; Caimi L; Imberti L
    J Immunol; 2010 Dec; 185(12):7713-22. PubMed ID: 21057082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National experience with adenosine deaminase deficiency related SCID in Polish children.
    Dąbrowska-Leonik N; Piątosa B; Słomińska E; Bohynikova N; Bernat-Sitarz K; Bernatowska E; Wolska-Kuśnierz B; Kałwak K; Kołtan S; Dąbrowska A; Goździk J; Ussowicz M; Pac M
    Front Immunol; 2022; 13():1058623. PubMed ID: 36685585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.
    Cicalese MP; Ferrua F; Castagnaro L; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Roncarolo MG; Aiuti A
    Mol Ther; 2018 Mar; 26(3):917-931. PubMed ID: 29433935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy.
    Arredondo-Vega FX; Santisteban I; Richard E; Bali P; Koleilat M; Loubser M; Al-Ghonaium A; Al-Helali M; Hershfield MS
    Blood; 2002 Feb; 99(3):1005-13. PubMed ID: 11807006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
    Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
    J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
    Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
    Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy.
    Sauer AV; Morbach H; Brigida I; Ng YS; Aiuti A; Meffre E
    J Clin Invest; 2012 Jun; 122(6):2141-52. PubMed ID: 22622038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-Onset Combined Immunodeficiency with a Novel IL2RG Mutation and Probable Revertant Somatic Mosaicism.
    Okuno Y; Hoshino A; Muramatsu H; Kawashima N; Wang X; Yoshida K; Wada T; Gunji M; Toma T; Kato T; Shiraishi Y; Iwata A; Hori T; Kitoh T; Chiba K; Tanaka H; Sanada M; Takahashi Y; Nonoyama S; Ito M; Miyano S; Ogawa S; Kojima S; Kanegane H
    J Clin Immunol; 2015 Oct; 35(7):610-4. PubMed ID: 26407811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.